Cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment

Eosinophilic fasciitis is a rare connective tissue disease of unknown etiology. Therapeutic options include high-dose corticosteroids and other immunosuppressive drugs. We present a typical eosinophilic fasciitis case, which did not respond to first-line treatment, but improved remarkably after infliximab administration. This report demonstrates that in case of initial treatment failure, infliximab might be a relatively safe and effective way of eosinophilic fasciitis management.

Download Full-text

Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort

BMC Cancer ◽

10.1186/s12885-021-08270-0 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Rafaela Pirolli ◽

Viviane Teixeira Loiola de Alencar ◽

Felipe Leonardo Estati ◽

Adriana Regina Gonçalves Ribeiro ◽

Daniella Yumi Tsuji Honda ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Propensity Score ◽

Ovarian Carcinoma ◽

Matched Cohort ◽

Line Treatment ◽

First Line ◽

Western Population ◽

Dose Dense ◽

First Line Treatment

Abstract Background Benefit of carboplatin and dose-dense weekly paclitaxel (ddCT) in first line treatment of ovarian cancer patients has been different in Western and Asian studies. In the present study we compare progression-free survival (PFS) of ddCT to three-weekly carboplatin and paclitaxel (CT) in first-line treatment of ovarian carcinoma in a single institution in a Western population. Materials and methods We conducted a retrospective review of medical records from patients with ovarian carcinoma treated in a tertiary cancer center from 2007 to 2018. All patients treated with ddCT or CT in the first-line setting were included. Patients who received first-line bevacizumab were not included. PFS and overall survival (OS) were compared in a propensity score-matched cohort to address selection bias. Patients were matched according to age, ECOG performance status, CA 125, FIGO stage, residual disease, and histological subtype, in a 1:2 ratio. Results Five hundred eighty-eight patients were eligible for propensity score matching, the final cohort consisted of 69 patients treated with ddCT and 138 CT group. Baseline characteristics were well-balanced. After a median follow-up of 65.1 months, median PFS was 29.3 vs 20.0 months, favouring ddCT treatment (p = 0.035). In the multivariate cox regression ddCT showed a 18% lower risk of progression (HR 0.82, 95% CI 0.68–0.99, p = 0.04). Overall survival data is immature, but suggested better outcomes for ddCT (not reached versus 78.8 months; p = 0.07). Conclusion Our retrospective study has shown superior PFS of ddCT over CT regimen in first-line treatment of ovarian carcinoma in a Western population not treated with bevacizumab.

Download Full-text

595 EFFICACIES OF HYBRID, HIGH-DOSE DUAL AND BISMUTH QUADRUPLE THERAPIES IN THE FIRST-LINE TREATMENT OF H PYLORI INFECTION — A MULTICENTER RANDOMIZED CONTROLLED TRIAL

Gastroenterology ◽

10.1016/s0016-5085(21)01027-1 ◽

2021 ◽

Vol 160 (6) ◽

pp. S-115-S-116

Author(s):

Ping-I Hsu ◽

Jyh-Chin Yang ◽

Seng-Kee Chuah ◽

Kuan-Yang Chen ◽

Yu-Hwa Liu ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Controlled Trial ◽

High Dose ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

Multicenter Randomized Controlled Trial ◽

H Pylori ◽

First Line Treatment

Download Full-text

Current Treatment Approaches to Newly Diagnosed Multiple Myeloma

Oncology Research and Treatment ◽

10.1159/000520504 ◽

2021 ◽

Vol 44 (12) ◽

pp. 690-699

Author(s):

Susanne Ghandili ◽

Katja C. Weisel ◽

Carsten Bokemeyer ◽

Lisa Beatrice Leypoldt

Keyword(s):

Multiple Myeloma ◽

Monoclonal Antibody ◽

Plasma Cell ◽

Cell Clone ◽

Unmet Need ◽

Continuous Treatment ◽

High Dose ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Background: Multiple myeloma is a so far incurable malignant plasma cell disorder. During the past 2 decades, treatment paradigms substantially changed when novel drugs were introduced initially in treatment of relapsed disease and subsequently also in first-line treatment. Summary: Up to now, first-line treatment differs between patients initially classified as transplant eligible and those who are considered as nontransplant eligible. Transplant-eligible patients receive a primary proteasome inhibitor (PI)-based induction which is being combined with an immunomodulating agent and a CD38-directed monoclonal antibody followed by high-dose melphalan therapy and autologous stem cell transplantation with subsequent maintenance treatment with lenalidomide. Patients who are considered as nontransplant eligible receive upfront treatment preferentially with a continuous combination treatment either with a CD38-directed monoclonal antibody in combination with the immunomodulating agent lenalidomide or a lenalidomide-PI combination followed by lenalidomide maintenance. Key Messages: Primary goal of the initiated treatment is to induce a rapid and deep remission which ideally leads to an eradication of the residual plasma cell clone in sense of a minimal residual disease negativity. Achievement of long-term remission with limited toxicity despite continuous treatment strategies and maintenance or improvement of life-quality is key. Despite successful treatment options, specific difficult-to-treat subgroups, especially patients with high-risk myeloma remain with inferior prognosis and a clear unmet need for novel therapeutic strategies. Future concepts will evaluate cellular treatments and other innovative immunotherapies in first-line treatment in curative intention.

Download Full-text